Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Assembly Biosciences, Inc. (ASMB)
USD26.61
-0.15 (-0.55%)
US NASDAQ Healthcare Biotechnology
Address
331 Oyster Point Boulevard 94080
South San Francisco, CA, US
South San Francisco, CA, US
CEO
Jason A. Okazaki
Website
assemblybio.com
IPO
2010-12-17
CIK 1426800 ISIN US0453962070
Description
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD26.61
-0.15 (-0.55%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
196.0K
Beta
1.09
Float Shares
10.35M
Free Float %
65.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.25% | -2.59% | +7.00% | +16.56% | -15.17% | -10.59% | +146.23% | +141.35% | -36.65% | -46.65% | -91.96% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (11 ratings, all time)
Buy
Price Targets & DCF
Current price
26.61
Low
40.00
+50.3%
Consensus
40.00
+50.3%
Median
40.00
+50.3%
High
40.00
+50.3%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 3 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 2 |
39.00
+46.5%
|
| All Time | 4 |
37.25
+40.0%
|
Quality scores
Altman Z-Score
4.00
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+153.5% ★ Q1'26: -12.8% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+91.8% ★ Q1'26: +53.8% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-69.6% Q1'26: -269.3% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-16.8% Q1'26: -138.4% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: +178.4% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+86.7% Q1'26: +125.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.22× Q1'26: -0.05× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 2 EPS Ana. |
Dec 2027 3 Rev. Ana. 2 EPS Ana. |
Dec 2028 3 Rev. Ana. 2 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
9.02M
est: 7.09M (+27.2%)
|
14.80M
est: 14.88M (-0.5%)
|
15.96M
est: 14.81M (+7.8%)
|
79.11M
est: 82.01M (-3.5%)
|
6.25M
est: 7.41M (-15.6%)
|
7.16M
est: 21.48M (-66.7%)
|
28.52M
est: 24.60M (+15.9%)
|
72.30M
est: 37.14M (+94.7%)
|
58.29M
56.35M – 60.24M
+57.0% YoY
|
43.00M
41.57M – 44.43M
-26.2% YoY
|
65.50M
63.32M – 67.68M
+52.3% YoY
|
28.00M
27.07M – 28.93M
-57.3% YoY
|
123.83M
119.70M – 127.95M
+342.2% YoY
|
| EBITDA |
-52.01M
est: -3.88M (-1,239.1%)
|
-92.74M
est: -75.54M (-22.8%)
|
-103.73M
est: -8.11M (-1,179.2%)
|
-58.40M
est: -18.98M (-207.6%)
|
-90.58M
est: -4.06M (-2,131.4%)
|
-64.20M
est: -9.30M (-589.9%)
|
-45.29M
est: -10.66M (-325.0%)
|
-11.99M
est: -16.09M (+25.5%)
|
-25.25M
-26.09M – -24.41M
-57.0% YoY
|
-18.63M
-19.25M – -18.01M
+26.2% YoY
|
-28.37M
-29.32M – -27.43M
-52.3% YoY
|
-12.13M
-12.53M – -11.72M
+57.3% YoY
|
-53.64M
-55.43M – -51.85M
-342.2% YoY
|
| EBIT |
-52.23M
est: -3.90M (-1,240.5%)
|
-92.74M
est: -78.99M (-17.4%)
|
-104.22M
est: -8.13M (-1,181.2%)
|
-59.09M
est: -28.37M (-108.3%)
|
-91.05M
est: -4.07M (-2,135.8%)
|
-64.65M
est: -9.31M (-594.2%)
|
-45.42M
est: -10.66M (-325.9%)
|
-12.12M
est: -16.10M (+24.7%)
|
-25.27M
-26.11M – -24.43M
-57.0% YoY
|
-18.64M
-19.26M – -18.02M
+26.2% YoY
|
-28.40M
-29.34M – -27.45M
-52.3% YoY
|
-12.14M
-12.54M – -11.73M
+57.3% YoY
|
-53.68M
-55.47M – -51.89M
-342.2% YoY
|
| Net Income |
-42.81M
est: -212.02M (+79.8%)
|
-90.75M
est: -77.06M (-17.8%)
|
-97.63M
est: -269.84M (+63.8%)
|
-62.15M
est: -20.57M (-202.1%)
|
-129.86M
est: -151.31M (+14.2%)
|
-61.23M
est: -98.20M (+37.6%)
|
-40.18M
est: -75.73M (+46.9%)
|
-6.12M
est: -41.98M (+85.4%)
|
-50.35M
-78.75M – 36.54M
-19.9% YoY
|
-45.68M
-54.16M – -8.84M
+9.3% YoY
|
-15.52M
-50.57M – 7.74M
+66.0% YoY
|
-36.70M
-38.29M – -35.11M
-136.4% YoY
|
-19.88M
-20.74M – -19.02M
+45.8% YoY
|
| SGA |
17.02M
est: 14.04M (+21.3%)
|
34.80M
est: 29.45M (+18.2%)
|
34.86M
est: 29.31M (+18.9%)
|
36.86M
est: 162.34M (-77.3%)
|
28.78M
est: 14.67M (+96.1%)
|
22.91M
est: 41.68M (-45.0%)
|
18.01M
est: 47.74M (-62.3%)
|
19.61M
est: 72.07M (-72.8%)
|
113.12M
109.35M – 116.89M
+57.0% YoY
|
83.44M
80.66M – 86.22M
-26.2% YoY
|
127.10M
122.87M – 131.34M
+52.3% YoY
|
54.33M
52.53M – 56.14M
-57.3% YoY
|
240.30M
232.29M – 248.30M
+342.2% YoY
|
| EPS |
-24.10
est: -35.31 (+31.7%)
|
-39.80
est: -46.41 (+14.2%)
|
-27.80
est: -44.94 (+38.1%)
|
-15.00
est: -18.67 (+19.7%)
|
-36.00
est: -25.20 (-42.9%)
|
-13.38
est: -8.76 (-52.8%)
|
-6.69
est: -6.76 (+1.0%)
|
-0.55
est: -3.75 (+85.3%)
|
-1.88
-7.02 – 3.26
+49.8% YoY
|
-2.81
-4.83 – -0.79
-49.3% YoY
|
-1.91
-4.51 – 0.69
+32.0% YoY
|
-3.27
-3.42 – -3.13
-71.4% YoY
|
-1.77
-1.85 – -1.70
+45.8% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-04 | HC Wainwright & Co. | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-01 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-33.31M
OE per share TTM
-3.53
Owner's Yield
-6.37%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
21.2%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
69
Total invested
466.68M
Insider transactions (90d)
0
Beneficial owners (>5%)
21
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Gilead Sciences, Inc. | 13.07M | 19.90% | 13.07M | — | 13.07M | — | CO | — | 2023-10-25 | ↗ |
| 2 | David Kroin | 3.00M | 6.27% | — | 3.00M | — | — | HC, IN | United States | 2022-02-14 | ↗ |
| 3 | Deep Track Biotechnology Master Fund, Ltd. | 3.00M | 6.27% | — | 3.00M | — | — | CO | Cayman Islands | 2022-02-14 | ↗ |
| 4 | Deep Track Capital, LP | 3.00M | 6.27% | — | 3.00M | — | — | IA, OO | Delaware | 2022-02-14 | ↗ |
| 5 | see the Notes). | 2.39M | 11.00% | — | 2.39M | — | — | OO | Delaware | 2019-12-23 | ↗ |
| 6 | Satter | 2.23M | 4.70% | 2.23M | — | 2.23M | — | IN | — | 2022-02-10 | ↗ |
| 7 | The Vanguard Group - 23-1945930 | 2.21M | 4.61% | — | 21.8K | — | — | IA | Pennsylvania | 2022-02-09 | ↗ |
| 8 | (1) BlackRock, Inc. | 1.91M | 4.80% | 1.82M | — | 1.91M | — | HC | Delaware | 2021-07-12 | ↗ |
| 9 | Wellington Group Holdings LLP | 1.52M | 4.73% | — | 1.43M | — | — | HC | Massachusetts | 2020-01-08 | ↗ |
| 10 | Wellington Investment Advisors Holdings LLP | 1.52M | 4.73% | — | 1.43M | — | — | HC | Massachusetts | 2020-01-08 | ↗ |
| 11 | Wellington Management Group LLP | 1.52M | 4.73% | — | 1.43M | — | — | HC | Massachusetts | 2020-01-08 | ↗ |
| 12 | Rock Springs Capital LLC | 1.50M | 4.66% | — | 1.50M | — | — | HC, OO | Delaware | 2020-02-14 | ↗ |
| 13 | Rock Springs Capital Management LP | 1.50M | 4.66% | — | 1.50M | — | — | IA | Delaware | 2020-02-14 | ↗ |
| 14 | Rock Springs Capital Master Fund LP | 1.50M | 4.66% | — | 1.50M | — | — | PN | Cayman Islands | 2020-02-14 | ↗ |
| 15 | Armistice Capital Master Fund Ltd. | 1.16M | 4.40% | — | 1.16M | — | 1.16M | CO | Cayman Islands | 2020-02-14 | ↗ |
| 16 | Armistice Capital, LLC | 354.0K | 5.58% | — | 354.0K | — | — | IA, OO | Delaware | 2024-11-14 | ↗ |
| 17 | Steven Boyd | 354.0K | 5.58% | — | 354.0K | — | — | HC, IN | United States of America | 2024-11-14 | ↗ |
| 18 | Consonance Capital Opportunity Fund Management LP | 149.9K | 0.45% | — | 149.9K | — | — | IA, PN | Delaware USA | 2021-02-17 | ↗ |
| 19 | Consonance Capital Management LP | — | 0.00% | — | — | — | — | IA, PN | Delaware USA | 2022-02-14 | ↗ |
| 20 | Consonance Capman GP LLC | — | 0.00% | — | — | — | — | HC, OO | Delaware USA | 2022-02-14 | ↗ |
| 21 | Mitchell Blutt | — | 0.00% | — | — | — | — | HC, IN | USA | 2022-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2025 Q4
Investors holding
69
+10 vs prev Q
New positions
21
Closed positions
10
Increased
44
Reduced
14
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | GILEAD SCIENCES, INC. | 4.51M +— (+0.0%) | 153.23M +37.9M (+32.9%) | 58.85% +0.000 pp | 7.92% +1.479 pp | USD20.78 +63.7% | 5 qtrs — |
| 2 | FARALLON CAPITAL MANAGEMENT LLC | 1.23M +— (+0.0%) | 41.75M +10.3M (+32.9%) | 16.03% +0.000 pp | 0.20% +0.068 pp | USD25.60 +32.9% | 2 qtrs — |
| 3 | RA CAPITAL MANAGEMENT, L.P. | 1.02M +— (+0.0%) | 34.70M +8.6M (+32.9%) | 13.33% +0.000 pp | 0.36% +0.034 pp | USD25.60 +32.9% | 2 qtrs — |
| 4 | COMMODORE CAPITAL LP | 1.00M +— (+0.0%) | 34.01M +8.4M (+32.9%) | 13.06% +0.000 pp | 2.26% +1.014 pp | USD25.60 +32.9% | 2 qtrs — |
| 5 | JANUS HENDERSON GROUP PLC | 837.9K +85.3K (+11.3%) | 28.54M +9.3M (+48.4%) | 10.94% +1.114 pp | 0.01% +0.004 pp | USD26.46 +28.5% | 2 qtrs — |
| 6 | PARADIGM BIOCAPITAL ADVISORS LP | 665.3K +665.3K (+100.0%) | 22.63M +22.6M (+100.0%) | 8.69% +8.689 pp | 0.58% +0.578 pp | USD34.01 +0.0% | 1 qtrs NEW |
| 7 | POINT72 ASSET MANAGEMENT, L.P. | 600.6K +304.6K (+102.9%) | 20.43M +12.8M (+169.6%) | 7.85% +3.979 pp | 0.02% +0.010 pp | USD29.87 +13.9% | 2 qtrs — |
| 8 | VANGUARD GROUP INC | 572.9K +70.8K (+14.1%) | 19.48M +6.6M (+51.6%) | 7.48% +0.925 pp | 0.00% +0.000 pp | USD21.27 +59.9% | 8 qtrs — |
| 9 | BLACKSTONE INC. | 318.8K -129.0K (-28.8%) | 10.84M -622.6K (-5.4%) | 4.16% -1.685 pp | 0.04% -0.003 pp | USD25.60 +32.9% | 2 qtrs — |
| 10 | PARKMAN HEALTHCARE PARTNERS LLC | 249.4K -1.6K (-0.6%) | 8.48M +2.1M (+32.0%) | 3.26% -0.021 pp | 0.81% +0.137 pp | USD25.60 +32.9% | 2 qtrs — |
| 11 | FRANKLIN RESOURCES INC | 210.5K -27.6K (-11.6%) | 7.16M -4.3M (-37.3%) | 2.75% -0.361 pp | 0.00% -0.001 pp | USD25.60 +32.9% | 2 qtrs — |
| 12 | BLACKROCK, INC. | 192.3K +22.1K (+13.0%) | 6.54M +2.2M (+50.1%) | 2.51% +0.289 pp | 0.00% +0.000 pp | USD21.87 +55.5% | 6 qtrs — |
| 13 | B GROUP, INC. | 175.7K +— (+0.0%) | 5.98M +1.5M (+32.9%) | 2.30% +0.000 pp | 4.41% +1.104 pp | USD11.14 +205.3% | 5 qtrs — |
| 14 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 161.0K +161.0K (+100.0%) | 5.48M +5.5M (+100.0%) | 2.10% +2.103 pp | 0.01% +0.008 pp | USD34.01 +0.0% | 1 qtrs NEW |
| 15 | EVERSEPT PARTNERS, LP | 159.7K +159.7K (+100.0%) | 5.43M +5.4M (+100.0%) | 2.09% +2.086 pp | 0.27% +0.274 pp | USD34.01 +0.0% | 1 qtrs NEW |
| 16 | STEMPOINT CAPITAL LP | 156.7K +90.6K (+137.0%) | 5.33M +3.6M (+214.9%) | 2.05% +1.183 pp | 0.91% +0.575 pp | USD30.46 +11.7% | 2 qtrs — |
| 17 | GEODE CAPITAL MANAGEMENT, LLC | 131.3K +1.2K (+0.9%) | 4.47M +1.1M (+34.1%) | 1.72% +0.016 pp | 0.00% +0.000 pp | USD20.85 +63.1% | 8 qtrs — |
| 18 | MARSHALL WACE, LLP | 129.1K +43.9K (+51.5%) | 4.39M +2.2M (+101.2%) | 1.69% +0.573 pp | 0.00% +0.002 pp | USD28.46 +19.5% | 6 qtrs — |
| 19 | PATIENT SQUARE CAPITAL LP | 127.0K -8.2K (-6.1%) | 4.32M +858.6K (+24.8%) | 1.66% -0.107 pp | 0.92% -0.001 pp | USD25.60 +32.9% | 2 qtrs — |
| 20 | CAPTION MANAGEMENT, LLC | 106.6K +106.6K (+100.0%) | 3.63M +3.6M (+100.0%) | 1.39% +1.392 pp | 0.02% +0.025 pp | USD34.01 +0.0% | 1 qtrs NEW |
| 21 | MILLENNIUM MANAGEMENT LLC | 98.2K +76.6K (+354.6%) | 3.34M +2.8M (+503.9%) | 1.28% +1.001 pp | 0.00% +0.001 pp | USD32.16 +5.8% | 2 qtrs — |
| 22 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 80.4K -50.6K (-38.6%) | 2.73M -620.1K (-18.5%) | 1.05% -0.661 pp | 0.00% 0.000 pp | USD25.60 +32.9% | 7 qtrs — |
| 23 | SUPERSTRING CAPITAL MANAGEMENT LP | 65.3K +65.3K (+100.0%) | 2.22M +2.2M (+100.0%) | 0.85% +0.853 pp | 1.19% +1.189 pp | USD34.01 +0.0% | 1 qtrs NEW |
| 24 | SCHONFELD STRATEGIC ADVISORS LLC | 54.2K -67.7K (-55.5%) | 1.84M -1.3M (-40.9%) | 0.71% -0.884 pp | 0.01% -0.010 pp | USD25.60 +32.9% | 2 qtrs — |
| 25 | JANE STREET GROUP, LLC | 53.7K +19.9K (+58.8%) | 1.83M +960.4K (+110.9%) | 0.70% +0.260 pp | 0.00% +0.000 pp | USD28.71 +18.5% | 2 qtrs — |
| 26 | STATE STREET CORP | 53.0K +8.2K (+18.2%) | 1.80M +654.9K (+57.1%) | 0.69% +0.107 pp | 0.00% +0.000 pp | USD23.61 +44.0% | 8 qtrs — |
| 27 | JPMORGAN CHASE & CO | 48.2K +48.2K (+687,885.7%) | 1.64M +1.6M (+914,921.2%) | 0.63% +0.629 pp | 0.00% +0.000 pp | USD34.01 +0.0% | 8 qtrs — |
| 28 | QUBE RESEARCH & TECHNOLOGIES LTD | 42.2K +31.2K (+282.5%) | 1.43M +1.2M (+408.1%) | 0.55% +0.407 pp | 0.00% +0.001 pp | USD31.81 +6.9% | 2 qtrs — |
| 29 | NORTHERN TRUST CORP | 41.2K +1.3K (+3.2%) | 1.40M +379.3K (+37.1%) | 0.54% +0.017 pp | 0.00% +0.000 pp | USD18.15 +87.4% | 8 qtrs — |
| 30 | MONIMUS CAPITAL MANAGEMENT, LP | 38.3K -3.8K (-9.0%) | 1.30M +225.7K (+21.0%) | 0.50% -0.049 pp | 0.86% +0.196 pp | USD15.78 +115.5% | 5 qtrs — |
| 31 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 37.8K +37.8K (+100.0%) | 1.29M +1.3M (+100.0%) | 0.49% +0.494 pp | 0.00% +0.001 pp | USD34.01 +0.0% | 1 qtrs NEW |
| 32 | PALUMBO WEALTH MANAGEMENT LLC | 37.3K +2.5K (+7.2%) | 1.27M +377.9K (+42.4%) | 0.49% +0.033 pp | 0.31% +0.029 pp | USD20.20 +68.4% | 5 qtrs — |
| 33 | GOLDMAN SACHS GROUP INC | 34.8K +17.1K (+97.1%) | 1.18M +731.4K (+161.8%) | 0.45% +0.224 pp | 0.00% +0.000 pp | USD29.74 +14.4% | 2 qtrs — |
| 34 | CITADEL ADVISORS LLC | 32.9K -21.0K (-39.0%) | 1.12M -261.5K (-19.0%) | 0.43% -0.275 pp | 0.00% +0.000 pp | USD18.69 +82.0% | 7 qtrs — |
| 35 | EAM INVESTORS, LLC | 29.5K +451.0 (+1.6%) | 1.00M +259.8K (+34.9%) | 0.39% +0.006 pp | 0.11% +0.027 pp | USD25.73 +32.2% | 2 qtrs — |
| 36 | TREXQUANT INVESTMENT LP | 28.3K +15.8K (+125.7%) | 961.7K +641.0K (+199.9%) | 0.37% +0.206 pp | 0.01% +0.005 pp | USD30.28 +12.3% | 2 qtrs — |
| 37 | 683 CAPITAL MANAGEMENT, LLC | 27.9K +27.9K (+100.0%) | 947.6K +947.6K (+100.0%) | 0.36% +0.364 pp | 0.04% +0.041 pp | USD34.01 +0.0% | 1 qtrs NEW |
| 38 | ELLSWORTH ADVISORS, LLC | 29.7K -215.0 (-0.7%) | 889.4K +37.6K (+4.4%) | 0.39% -0.003 pp | 0.18% -0.006 pp | USD25.60 +32.9% | 2 qtrs — |
| 39 | FEDERATED HERMES, INC. | 25.4K +— (+0.0%) | 863.7K +213.6K (+32.9%) | 0.33% +0.000 pp | 0.00% +0.000 pp | USD12.90 +163.6% | 8 qtrs — |
| 40 | BARCLAYS PLC | 24.7K +21.7K (+715.2%) | 841.4K +795.5K (+1,731.2%) | 0.32% +0.284 pp | 0.00% +0.000 pp | USD31.51 +7.9% | 8 qtrs — |
| 41 | MORGAN STANLEY | 22.5K +19.0K (+538.9%) | 766.4K +676.1K (+748.8%) | 0.29% +0.248 pp | 0.00% +0.000 pp | USD31.52 +7.9% | 8 qtrs — |
| 42 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 20.8K +9.6K (+86.5%) | 707.5K +421.9K (+147.7%) | 0.27% +0.126 pp | 0.00% +0.001 pp | USD29.50 +15.3% | 5 qtrs — |
| 43 | ADAR1 CAPITAL MANAGEMENT, LLC | 19.7K +800.0 (+4.2%) | 671.6K +186.6K (+38.5%) | 0.26% +0.010 pp | 0.05% +0.004 pp | USD25.94 +31.1% | 2 qtrs — |
| 44 | SEI INVESTMENTS CO | 17.7K +17.7K (+100.0%) | 603.5K +603.5K (+100.0%) | 0.23% +0.232 pp | 0.00% +0.001 pp | USD34.01 +0.0% | 1 qtrs NEW |
| 45 | OMERS ADMINISTRATION CORP | 15.6K +15.6K (+100.0%) | 530.5K +530.5K (+100.0%) | 0.20% +0.204 pp | 0.00% +0.004 pp | USD34.01 +0.0% | 1 qtrs NEW |
| 46 | HUDSON BAY CAPITAL MANAGEMENT LP | 15.1K +15.1K (+100.0%) | 511.9K +511.9K (+100.0%) | 0.20% +0.197 pp | 0.00% +0.002 pp | USD34.01 +0.0% | 1 qtrs NEW |
| 47 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 13.9K +13.9K (+100.0%) | 472.8K +472.8K (+100.0%) | 0.18% +0.182 pp | 0.01% +0.007 pp | USD34.01 +0.0% | 1 qtrs NEW |
| 48 | RAYMOND JAMES FINANCIAL INC | 13.1K +13.1K (+100.0%) | 444.9K +444.9K (+100.0%) | 0.17% +0.171 pp | 0.00% +0.000 pp | USD34.01 +0.0% | 3 qtrs — |
| 49 | GSA CAPITAL PARTNERS LLP | 12.7K +279.0 (+2.2%) | 432.0K +114.0K (+35.8%) | 0.17% +0.004 pp | 0.04% +0.011 pp | USD18.47 +84.1% | 3 qtrs — |
| 50 | ACADIAN ASSET MANAGEMENT LLC | 12.4K -10.8K (-46.6%) | 422.0K -173.0K (-29.1%) | 0.16% -0.142 pp | 0.00% 0.000 pp | USD13.99 +143.1% | 8 qtrs — |
| 51 | ENGINEERS GATE MANAGER LP | 10.4K +10.4K (+100.0%) | 352.9K +352.9K (+100.0%) | 0.14% +0.136 pp | 0.00% +0.004 pp | USD34.01 +0.0% | 1 qtrs NEW |
| 52 | UBS GROUP AG | 9.8K -6.0K (-38.0%) | 332.6K -71.0K (-17.6%) | 0.13% -0.078 pp | 0.00% +0.000 pp | USD24.07 +41.3% | 8 qtrs — |
| 53 | RENAISSANCE TECHNOLOGIES LLC | 9.2K -144.4K (-94.0%) | 314.3K -3.6M (-92.0%) | 0.12% -1.886 pp | 0.00% -0.005 pp | USD17.02 +99.8% | 8 qtrs — |
| 54 | VIRTUS INVESTMENT ADVISERS, INC. | 7.4K +7.4K (+100.0%) | 250.6K +250.6K (+100.0%) | 0.10% +0.096 pp | 0.07% +0.068 pp | USD34.01 +0.0% | 1 qtrs NEW |
| 55 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 6.7K +6.7K (+100.0%) | 228.0K +228.0K (+100.0%) | 0.09% +0.088 pp | 0.00% +0.000 pp | USD34.01 +0.0% | 1 qtrs NEW |
| 56 | BANK OF AMERICA CORP /DE/ | 5.1K +1.7K (+51.6%) | 173.8K +87.5K (+101.4%) | 0.07% +0.023 pp | 0.00% +0.000 pp | USD28.36 +19.9% | 7 qtrs — |
| 57 | — | 4.3K +4.3K (+100.0%) | 146.8K +146.8K (+100.0%) | 0.06% +0.056 pp | 0.11% +0.112 pp | USD34.01 +0.0% | 1 qtrs NEW |
| 58 | CANADA PENSION PLAN INVESTMENT BOARD | 3.5K +3.5K (+100.0%) | 119.0K +119.0K (+100.0%) | 0.05% +0.046 pp | 0.00% +0.000 pp | USD34.01 +0.0% | 1 qtrs NEW |
| 59 | CITIGROUP INC | 2.2K +2.2K (+100.0%) | 74.9K +74.9K (+100.0%) | 0.03% +0.029 pp | 0.00% +0.000 pp | USD34.01 +0.0% | 1 qtrs NEW |
| 60 | TOWER RESEARCH CAPITAL LLC (TRC) | 607.00 +607.0 (+100.0%) | 20.6K +20.6K (+100.0%) | 0.01% +0.008 pp | 0.00% +0.001 pp | USD34.01 +0.0% | 8 qtrs — |
| 61 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 260.00 +— (+0.0%) | 8.8K +2.2K (+32.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD15.78 +115.5% | 5 qtrs — |
| 62 | RHUMBLINE ADVISERS | 190.00 +— (+0.0%) | 6.5K +1.6K (+32.8%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD12.89 +163.8% | 8 qtrs — |
| 63 | FARTHER FINANCE ADVISORS, LLC | 154.00 +154.0 (+100.0%) | 5.2K +5.2K (+100.0%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD34.01 +0.0% | 1 qtrs NEW |
| 64 | ADVISOR GROUP HOLDINGS, INC. | 100.00 +— (+0.0%) | 3.4K +841.0 (+32.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD18.11 +87.8% | 6 qtrs — |
| 65 | US BANCORP \DE\ | 59.00 +59.0 (+100.0%) | 2.0K +2.0K (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD34.00 +0.0% | 1 qtrs NEW |
| 66 | EVERSOURCE WEALTH ADVISORS, LLC | 55.00 +— (+0.0%) | 1.9K +463.0 (+32.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD12.89 +163.8% | 8 qtrs — |
| 67 | ALLWORTH FINANCIAL LP | 32.00 +32.0 (+100.0%) | 1.1K +1.1K (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD34.00 +0.0% | 1 qtrs NEW |
| 68 | QUADRANT CAPITAL GROUP LLC | 22.00 +— (+0.0%) | 749.00 +185.0 (+32.8%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD25.59 +32.9% | 2 qtrs — |
| 69 | BNP PARIBAS ARBITRAGE, SNC | 2.00 -56.0 (-96.6%) | 68.00 -1.4K (-95.4%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD15.50 +119.4% | 5 qtrs — |
| 70 | QUADRATURE CAPITAL LTD | — -17.9K (-100.0%) | — -459.1K (-100.0%) | 0.00% -0.234 pp | 0.00% -0.005 pp | USD— | 2 qtrs SOLD |
| 71 | FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | — -456.2K (-100.0%) | — -11.7M (-100.0%) | 0.00% -5.960 pp | 0.00% -0.350 pp | USD— | 2 qtrs SOLD |
| 72 | WALLEYE CAPITAL LLC | — -24.5K (-100.0%) | — -627.2K (-100.0%) | 0.00% -0.320 pp | 0.00% -0.002 pp | USD— | 2 qtrs SOLD |
| 73 | WELLS FARGO & COMPANY/MN | — -145.0 (-100.0%) | — -3.7K (-100.0%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD— | 4 qtrs SOLD |
| 74 | XTX TOPCO LTD | — -12.8K (-100.0%) | — -327.8K (-100.0%) | 0.00% -0.167 pp | 0.00% -0.017 pp | USD— | 2 qtrs SOLD |
| 75 | SBI SECURITIES CO., LTD. | — -68.0 (-100.0%) | — -1.7K (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 5 qtrs SOLD |
| 76 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | — -15.2K (-100.0%) | — -389.8K (-100.0%) | 0.00% -0.199 pp | 0.00% -0.008 pp | USD— | 8 qtrs SOLD |
| 77 | BIOIMPACT CAPITAL LLC | — -39.7K (-100.0%) | — -1.0M (-100.0%) | 0.00% -0.518 pp | 0.00% -0.166 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 39 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Virtus Biotech Clinical Trials ETF BBC | 0.73% | 422.8K | 0.65% |
| 2 | iShares Micro-Cap ETF IWC | 0.06% | 907.9K | 0.60% |
| 3 | Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF GSSC | 0.02% | 252.6K | 0.20% |
| 4 | iShares Russell 2000 Value ETF IWN | 0.02% | 2.42M | 0.24% |
| 5 | Avantis U.S. Small Cap Equity ETF AVSC | 0.01% | 331.9K | 0.25% |
| 6 | Fidelity Enhanced Small Cap ETF FESM | 0.01% | 520.2K | 0.28% |
| 7 | Global X - Russell 2000 ETF RSSL | 0.01% | 126.0K | 0.08% |
| 8 | Invesco Russell 2000 UCITS ETF RTYS.L | 0.01% | 27.3K | 0.25% |
| 9 | Xtrackers Russell 2000 UCITS ETF 1C XRSU.L | 0.01% | 241.2K | 0.30% |
| 10 | iShares Russell 2000 BuyWrite ETF IWMW | 0.01% | 4.7K | 0.39% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.25
Neutral
Ratio by volume
3.00
Bullish
Buys
5
Sells
4
Shares acquired
178.8K
Shares disposed
525.00
Cash buys
—
Cash sales
4.00
Net activity
+178,225
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-30 | White Nicole S | Officer | S-Sale | D | Common Stock | 188 | 26.65 | 5.0K | 37,486 | D | ↗ |
| 2026-03-30 | Bjorkquist Jeanette M | Officer | S-Sale | D | Common Stock | 312 | 26.65 | 8.3K | 11,105 | D | ↗ |
| 2026-03-29 | White Nicole S | Officer | A-Award | A | Common Stock | 26,000 | 0.00 | — | 37,674 | D | ↗ |
| 2026-03-29 | Okazaki Jason A | Director / Officer | A-Award | A | Common Stock | 94,250 | 0.00 | — | 111,916 | D | ↗ |
| 2026-03-29 | Gaggar Anuj | Officer | A-Award | A | Common Stock | 26,000 | 0.00 | — | 28,000 | D | ↗ |
| 2026-03-29 | Delaney William E IV | Officer | A-Award | A | Common Stock | 26,000 | 0.00 | — | 45,642 | D | ↗ |
| 2026-03-29 | Bjorkquist Jeanette M | Officer | A-Award | A | Common Stock | 6,500 | 0.00 | — | 11,417 | D | ↗ |
| 2025-08-08 | GILEAD SCIENCES, INC. | 10% Owner | P-Purchase | A | Common Stock | 2,295,920 | 0.00 | 2.3K | 4,505,391 | D | ↗ |
| 2025-06-16 | Bjorkquist Jeanette M | Officer | A-Award | A | Stock Option (right to buy) | 600 | 17.24 | 10.3K | 600 | D | ↗ |
| 2025-06-05 | RINGO WILLIAM R | Director | A-Award | A | Stock Option (right to buy) | 3,500 | 15.81 | 55.3K | 3,500 | D | ↗ |
| 2025-06-05 | McHutchison John G | Director | A-Award | A | Stock Option (right to buy) | 3,500 | 15.81 | 55.3K | 3,500 | D | ↗ |
| 2025-06-05 | Mahony Susan | Director | A-Award | A | Stock Option (right to buy) | 3,500 | 15.81 | 55.3K | 3,500 | D | ↗ |
| 2025-06-05 | Johnson-Pratt Lisa | Director | A-Award | A | Stock Option (right to buy) | 3,500 | 15.81 | 55.3K | 3,500 | D | ↗ |
| 2025-06-05 | Houghton Michael | Director | A-Award | A | Stock Option (right to buy) | 3,500 | 15.81 | 55.3K | 3,500 | D | ↗ |
| 2025-06-05 | Consylman Gina | Director | A-Award | A | Stock Option (right to buy) | 3,500 | 15.81 | 55.3K | 3,500 | D | ↗ |
| 2025-06-05 | ALTIG ANTHONY E | Director | A-Award | A | Stock Option (right to buy) | 3,500 | 15.81 | 55.3K | 3,500 | D | ↗ |
| 2025-03-31 | White Nicole S | Officer | S-Sale | D | Common Stock | 197 | 9.85 | 1.9K | 11,674 | D | ↗ |
| 2025-03-31 | Okazaki Jason A | Director / Officer | S-Sale | D | Common Stock | 355 | 9.85 | 3.5K | 14,757 | D | ↗ |
| 2025-03-31 | McHutchison John G | Director | S-Sale | D | Common Stock | 757 | 9.85 | 7.5K | 18,347 | D | ↗ |
| 2025-03-31 | Bjorkquist Jeanette M | Officer | S-Sale | D | Common Stock | 180 | 9.85 | 1.8K | 4,617 | D | ↗ |
| 2025-03-29 | White Nicole S | Officer | A-Award | A | Stock Option (right to buy) | 20,400 | 10.62 | 216.6K | 20,400 | D | ↗ |
| 2025-03-29 | Okazaki Jason A | Director / Officer | A-Award | A | Stock Option (right to buy) | 71,100 | 10.62 | 755.1K | 71,100 | D | ↗ |
| 2025-03-29 | Gaggar Anuj | Officer | A-Award | A | Stock Option (right to buy) | 24,200 | 10.62 | 257.0K | 24,200 | D | ↗ |
| 2025-03-29 | Delaney William E IV | Officer | A-Award | A | Stock Option (right to buy) | 25,500 | 10.62 | 270.8K | 25,500 | D | ↗ |
| 2025-03-29 | Bjorkquist Jeanette M | Officer | A-Award | A | Stock Option (right to buy) | 1,900 | 10.62 | 20.2K | 1,900 | D | ↗ |
| 2024-12-30 | Houghton Michael | Director | P-Purchase | A | Common Stock | 3,202 | 15.61 | 50.0K | 3,202 | I | ↗ |
| 2024-12-19 | GILEAD SCIENCES, INC. | 10% Owner | P-Purchase | A | Common Stock | 940,499 | 21.37 | 20.10M | 2,209,471 | D | ↗ |
| 2024-11-25 | Schornstein Alexander | 10% Owner | P-Purchase | A | Common Stock | 5,000 | 14.85 | 74.3K | 728,113 | D | ↗ |
| 2024-11-22 | Schornstein Alexander | 10% Owner | P-Purchase | A | Common Stock | 17,024 | 14.87 | 253.1K | 720,137 | D | ↗ |
| 2024-11-18 | White Nicole S | Officer | S-Sale | D | Common Stock | 40 | 16.29 | 651.60 | 11,871 | D | ↗ |
| 2024-10-08 | Schornstein Alexander | 10% Owner | P-Purchase | A | Common Stock | 10,000 | 14.58 | 145.8K | 703,113 | D | ↗ |
| 2024-10-03 | White Nicole S | Officer | S-Sale | D | Common Stock | 157 | 14.81 | 2.3K | 11,911 | D | ↗ |
| 2024-10-03 | Okazaki Jason A | Director / Officer | S-Sale | D | Common Stock | 197 | 14.81 | 2.9K | 14,904 | D | ↗ |
| 2024-08-02 | White Nicole S | Officer | S-Sale | D | Common Stock | 785 | 14.23 | 11.2K | 12,068 | — | ↗ |
| 2024-08-02 | Okazaki Jason A | Director / Officer | S-Sale | D | Common Stock | 981 | 14.23 | 14.0K | 15,101 | — | ↗ |
| 2024-07-05 | Schornstein Alexander | 10% Owner | P-Purchase | A | Common Stock | 4,438 | 12.52 | 55.6K | 693,113 | — | ↗ |
| 2024-07-03 | Schornstein Alexander | 10% Owner | P-Purchase | A | Common Stock | 4,562 | 12.29 | 56.1K | 688,675 | — | ↗ |
| 2024-06-17 | GILEAD SCIENCES, INC. | 10% Owner | P-Purchase | A | Common Stock | 179,500 | 0.00 | 179.50 | 1,268,972 | — | ↗ |
| 2024-05-29 | RINGO WILLIAM R | Director | A-Award | A | Stock Option (right to buy) | 2,750 | 15.06 | 41.4K | 2,750 | — | ↗ |
| 2024-05-29 | McHutchison John G | Director | A-Award | A | Stock Option (right to buy) | 2,750 | 15.06 | 41.4K | 2,750 | — | ↗ |
| 2024-05-29 | Mahony Susan | Director | A-Award | A | Stock Option (right to buy) | 2,750 | 15.06 | 41.4K | 2,750 | — | ↗ |
| 2024-05-29 | Johnson-Pratt Lisa | Director | A-Award | A | Stock Option (right to buy) | 2,750 | 15.06 | 41.4K | 2,750 | — | ↗ |
| 2024-05-29 | Houghton Michael | Director | A-Award | A | Stock Option (right to buy) | 2,750 | 15.06 | 41.4K | 2,750 | — | ↗ |
| 2024-05-29 | Consylman Gina | Director | A-Award | A | Stock Option (right to buy) | 2,750 | 15.06 | 41.4K | 2,750 | — | ↗ |
| 2024-05-29 | ALTIG ANTHONY E | Director | A-Award | A | Stock Option (right to buy) | 2,750 | 15.06 | 41.4K | 2,750 | — | ↗ |
| 2024-05-23 | White Nicole S | Officer | S-Sale | D | Common Stock | 172 | 14.93 | 2.6K | 12,853 | — | ↗ |
| 2024-05-23 | Okazaki Jason A | Director / Officer | S-Sale | D | Common Stock | 549 | 14.93 | 8.2K | 16,082 | — | ↗ |
| 2024-05-23 | McHutchison John G | Director | S-Sale | D | Common Stock | 2,117 | 14.93 | 31.6K | 19,104 | — | ↗ |
| 2024-05-23 | Bjorkquist Jeanette M | Officer | S-Sale | D | Common Stock | 24 | 14.93 | 358.41 | 3,142 | — | ↗ |
| 2024-04-30 | White Nicole S | Officer | S-Sale | D | Common Stock | 1,255 | 12.71 | 15.9K | 13,025 | — | ↗ |
| 2024-04-30 | Okazaki Jason A | Director / Officer | S-Sale | D | Common Stock | 1,569 | 12.71 | 19.9K | 16,423 | — | ↗ |
| 2024-04-29 | White Nicole S | Officer | A-Award | A | Common Stock | 3,333 | 0.00 | — | 14,280 | — | ↗ |
| 2024-04-29 | Okazaki Jason A | Director / Officer | A-Award | A | Common Stock | 4,166 | 0.00 | — | 17,992 | — | ↗ |
| 2024-04-29 | Delaney William E IV | Officer | A-Award | A | Common Stock | 3,333 | 0.00 | — | 16,109 | — | ↗ |
| 2024-04-01 | White Nicole S | Officer | S-Sale | D | Common Stock | 197 | 13.07 | 2.6K | 10,947 | — | ↗ |
| 2024-04-01 | Okazaki Jason A | Director / Officer | S-Sale | D | Common Stock | 354 | 13.07 | 4.6K | 13,826 | — | ↗ |
| 2024-04-01 | McHutchison John G | Director | S-Sale | D | Common Stock | 1,206 | 13.07 | 15.8K | 21,221 | — | ↗ |
| 2024-04-01 | Bjorkquist Jeanette M | Officer | S-Sale | D | Common Stock | 114 | 13.07 | 1.5K | 3,166 | — | ↗ |
| 2024-03-29 | White Nicole S | Officer | A-Award | A | Stock Option (right to buy) | 17,500 | 13.30 | 232.8K | 17,500 | — | ↗ |
| 2024-03-29 | Okazaki Jason A | Director / Officer | A-Award | A | Stock Option (right to buy) | 65,000 | 13.30 | 864.5K | 65,000 | — | ↗ |
| 2024-03-29 | Delaney William E IV | Officer | A-Award | A | Stock Option (right to buy) | 20,000 | 13.30 | 266.0K | 20,000 | — | ↗ |
| 2024-03-29 | Bjorkquist Jeanette M | Officer | A-Award | A | Common Stock | 850 | 0.00 | — | 3,280 | — | ↗ |
| 2024-03-27 | Okazaki Jason A | Director / Officer | S-Sale | D | Common Stock | 392 | 12.87 | 5.0K | 14,180 | — | ↗ |
| 2024-03-13 | Cook Robert Donald II | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-01-18 | Schornstein Alexander | 10% Owner | P-Purchase | A | Common Stock | 345,086 | 0.80 | 276.1K | 8,209,372 | — | ↗ |
| 2024-01-17 | Schornstein Alexander | 10% Owner | P-Purchase | A | Common Stock | 299,994 | 0.78 | 235.2K | 7,864,286 | — | ↗ |
| 2023-12-07 | Cihlar Tomas | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-11-21 | Schornstein Alexander | 10% Owner | P-Purchase | A | Common Stock | 100,000 | 0.67 | 66.7K | 7,564,292 | — | ↗ |
| 2023-11-20 | Schornstein Alexander | 10% Owner | P-Purchase | A | Common Stock | 300,000 | 0.72 | 215.4K | 7,464,292 | — | ↗ |
| 2023-11-17 | White Nicole S | Officer | S-Sale | D | Common Stock | 477 | 0.69 | 328.65 | 93,774 | — | ↗ |
| 2023-11-08 | Gaggar Anuj | Officer | A-Award | A | Stock Options (right to buy) | 500,000 | 0.85 | 425.0K | 500,000 | — | ↗ |
| 2023-10-23 | Schornstein Alexander | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 6,060,000 | — | ↗ |
| 2023-10-16 | GILEAD SCIENCES, INC. | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 13,073,668 | — | ↗ |
| 2023-10-03 | White Nicole S | Officer | S-Sale | D | Common Stock | 1,891 | 0.80 | 1.5K | 94,251 | — | ↗ |
| 2023-10-03 | Okazaki Jason A | Director / Officer | S-Sale | D | Common Stock | 2,363 | 0.80 | 1.9K | 174,923 | — | ↗ |
| 2023-10-03 | Delaney William E IV | Officer | S-Sale | D | Common Stock | 1,891 | 0.80 | 1.5K | 150,853 | — | ↗ |
| 2023-10-02 | White Nicole S | Officer | A-Award | A | Common Stock | 10,000 | 0.00 | — | 96,142 | — | ↗ |
| 2023-10-02 | Okazaki Jason A | Director / Officer | A-Award | A | Common Stock | 12,500 | 0.00 | — | 177,286 | — | ↗ |
| 2023-10-02 | Delaney William E IV | Officer | A-Award | A | Common Stock | 10,000 | 0.00 | — | 152,744 | — | ↗ |
| 2023-09-13 | White Nicole S | Officer | — | D | Performance-based Restricted Stock Units | 25,000 | 0.00 | — | 0 | — | ↗ |
| 2023-08-02 | Okazaki Jason A | Director / Officer | S-Sale | D | Common Stock | 11,827 | 1.09 | 12.9K | 164,786 | — | ↗ |
| 2023-08-02 | Delaney William E IV | Officer | S-Sale | D | Common Stock | 9,461 | 1.09 | 10.3K | 142,744 | — | ↗ |
| 2023-07-24 | Bjorkquist Jeanette M | Officer | S-Sale | D | Common Stock | 844 | 1.07 | 900.38 | 26,688 | — | ↗ |
| 2023-06-22 | Okazaki Jason A | Director / Officer | A-Award | A | Common Stock | 50,000 | 0.00 | — | 176,613 | — | ↗ |
| 2023-06-22 | Delaney William E IV | Officer | A-Award | A | Common Stock | 40,000 | 0.00 | — | 152,205 | — | ↗ |
| 2023-05-30 | Delaney William E IV | Officer | S-Sale | D | Common Stock | 4,232 | 0.96 | 4.0K | 112,205 | — | ↗ |
| 2023-05-25 | RINGO WILLIAM R | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 0.97 | 19.4K | 20,000 | — | ↗ |
| 2023-05-25 | McHutchison John G | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 0.97 | 19.4K | 20,000 | — | ↗ |
| 2023-05-25 | Mahony Susan | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 0.97 | 19.4K | 20,000 | — | ↗ |
| 2023-05-25 | Johnson-Pratt Lisa | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 0.97 | 19.4K | 20,000 | — | ↗ |
| 2023-05-25 | Houghton Michael | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 0.97 | 19.4K | 20,000 | — | ↗ |
| 2023-05-25 | Consylman Gina | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 0.97 | 19.4K | 20,000 | — | ↗ |
| 2023-05-25 | ALTIG ANTHONY E | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 0.97 | 19.4K | 20,000 | — | ↗ |
| 2023-05-23 | Okazaki Jason A | Director / Officer | S-Sale | D | Common Stock | 6,561 | 1.04 | 6.8K | 126,613 | — | ↗ |
| 2023-05-23 | McHutchison John G | Director | S-Sale | D | Common Stock | 25,972 | 1.04 | 27.0K | 169,160 | — | ↗ |
| 2023-05-23 | Delaney William E IV | Officer | S-Sale | D | Common Stock | 6,561 | 1.04 | 6.8K | 116,437 | — | ↗ |
| 2023-05-23 | Bjorkquist Jeanette M | Officer | S-Sale | D | Common Stock | 274 | 1.04 | 285.04 | 27,532 | — | ↗ |
| 2023-05-22 | Okazaki Jason A | Director / Officer | A-Award | A | Common Stock | 35,000 | 0.00 | — | 133,174 | — | ↗ |
| 2023-05-22 | McHutchison John G | Director | A-Award | A | Common Stock | 117,500 | 0.00 | — | 295,132 | — | ↗ |
| 2023-05-22 | Delaney William E IV | Officer | A-Award | A | Common Stock | 35,000 | 0.00 | — | 122,998 | — | ↗ |
| 2023-05-22 | Bjorkquist Jeanette M | Officer | A-Award | A | Common Stock | 1,500 | 0.00 | — | 27,806 | — | ↗ |
| 2023-03-30 | Okazaki Jason A | Director / Officer | S-Sale | D | Common Stock | 4,247 | 0.82 | 3.5K | 98,174 | — | ↗ |
| 2023-03-30 | McHutchison John G | Director | S-Sale | D | Common Stock | 14,883 | 0.82 | 12.3K | 177,632 | — | ↗ |
| 2023-03-30 | Delaney William E IV | Officer | S-Sale | D | Common Stock | 3,421 | 0.82 | 2.8K | 85,498 | — | ↗ |
| 2023-03-30 | Bjorkquist Jeanette M | Officer | S-Sale | D | Common Stock | 774 | 0.82 | 637.16 | 23,806 | — | ↗ |
| 2023-03-29 | Okazaki Jason A | Director / Officer | A-Award | A | Stock Option (right to buy) | 470,000 | 0.89 | 418.3K | 470,000 | — | ↗ |
| 2023-03-29 | Delaney William E IV | Officer | A-Award | A | Stock Option (right to buy) | 140,000 | 0.89 | 124.6K | 140,000 | — | ↗ |
| 2023-03-29 | Bjorkquist Jeanette M | Officer | A-Award | A | Common Stock | 6,250 | 0.00 | — | 24,580 | — | ↗ |
| 2023-03-27 | Okazaki Jason A | Director / Officer | S-Sale | D | Common Stock | 4,693 | 1.02 | 4.8K | 102,421 | — | ↗ |
| 2023-02-16 | Okazaki Jason A | Director / Officer | A-Award | A | Common Stock | 12,500 | 0.00 | — | 107,114 | — | ↗ |
| 2023-02-16 | Delaney William E IV | Officer | A-Award | A | Common Stock | 10,000 | 0.00 | — | 88,919 | — | ↗ |
| 2023-02-16 | Bjorkquist Jeanette M | Officer | A-Award | A | Stock Option (right to buy) | 2,000 | 1.53 | 3.1K | 2,000 | — | ↗ |
| 2022-08-08 | McHutchison John G | Officer | S-Sale | D | Common Stock | 12,314 | 2.13 | 26.2K | 192,515 | — | ↗ |
| 2022-08-01 | Okazaki Jason A | Officer | A-Award | A | Stock Option (right to buy) | 250,000 | 0.00 | — | 250,000 | — | ↗ |
| 2022-08-01 | Delaney William E IV | Officer | A-Award | A | Stock Option (right to buy) | 200,000 | 0.00 | — | 200,000 | — | ↗ |
| 2022-07-25 | Samar Michael P. | Officer | S-Sale | D | Common Stock | 2,020 | 2.22 | 4.5K | 77,228 | — | ↗ |
| 2022-05-31 | Delaney William E IV | Officer | S-Sale | D | Common Stock | 4,164 | 1.92 | 8.0K | 76,419 | — | ↗ |
| 2022-05-25 | RINGO WILLIAM R | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-05-25 | Mahony Susan | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-05-25 | Johnson-Pratt Lisa | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-05-25 | Houghton Michael | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-05-25 | DiMarchi Richard D | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-05-25 | Consylman Gina | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-05-25 | ALTIG ANTHONY E | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-03-29 | Stamm Luisa M | Officer | A-Award | A | Performance-based Restricted Stock Units | 22,500 | 0.00 | — | 22,500 | — | ↗ |
| 2022-03-29 | Samar Michael P. | Officer | A-Award | A | Performance-based Restricted Stock Units | 26,250 | 0.00 | — | 26,250 | — | ↗ |
| 2022-03-29 | Okazaki Jason A | Officer | S-Sale | D | Common Stock | 1,269 | 2.17 | 2.8K | 94,614 | — | ↗ |
| 2022-03-29 | McHutchison John G | Director / Officer | A-Award | A | Stock Option (right to buy) | 335,000 | 2.30 | 770.5K | 335,000 | — | ↗ |
| 2022-03-29 | Delaney William E IV | Officer | A-Award | A | Performance-based Restricted Stock Units | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-03-28 | Okazaki Jason A | Officer | S-Sale | D | Common Stock | 4,617 | 2.24 | 10.4K | 64,633 | — | ↗ |
| 2021-08-09 | McHutchison John G | Director / Officer | S-Sale | D | Common Stock | 12,156 | 3.60 | 43.8K | 125,693 | — | ↗ |
| 2021-07-22 | Samar Michael P. | Officer | A-Award | A | Common Stock | 10,938 | 0.00 | — | 51,783 | — | ↗ |
| 2021-07-19 | Houghton Michael | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 3.50 | 105.0K | 30,000 | — | ↗ |
| 2021-06-04 | Samar Michael P. | Officer | — | D | Common Stock | 0 | 0.00 | — | 40,845 | — | ↗ |
| 2021-05-27 | Delaney William E IV | Officer | S-Sale | D | Common Stock | 4,129 | 4.03 | 16.6K | 53,121 | — | ↗ |
| 2021-05-20 | RINGO WILLIAM R | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 4.03 | 60.5K | 15,000 | — | ↗ |
| 2021-05-20 | Mahony Susan | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 4.03 | 60.5K | 15,000 | — | ↗ |
| 2021-05-20 | Johnson-Pratt Lisa | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-05-20 | HOLUBIAK MYRON Z | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 4.03 | 60.5K | 15,000 | — | ↗ |
| 2021-05-20 | DiMarchi Richard D | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 4.03 | 60.5K | 15,000 | — | ↗ |
| 2021-05-20 | Consylman Gina | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 4.03 | 60.5K | 15,000 | — | ↗ |
| 2021-05-20 | ALTIG ANTHONY E | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 4.03 | 60.5K | 15,000 | — | ↗ |
| 2021-03-29 | Stamm Luisa M | Officer | A-Award | A | Stock Option (right to buy) | 67,500 | 4.33 | 292.3K | 67,500 | — | ↗ |
| 2021-03-29 | Russo Thomas Joseph | Officer | A-Award | A | Stock Option (right to buy) | 67,500 | 4.33 | 292.3K | 67,500 | — | ↗ |
| 2021-03-29 | Okazaki Jason A | Officer | A-Award | A | Stock Option (right to buy) | 82,500 | 4.33 | 357.2K | 82,500 | — | ↗ |
| 2021-03-29 | McHutchison John G | Director / Officer | A-Award | A | Stock Option (right to buy) | 305,000 | 4.33 | 1.32M | 305,000 | — | ↗ |
| 2021-03-29 | Delaney William E IV | Officer | A-Award | A | Stock Option (right to buy) | 67,500 | 4.33 | 292.3K | 67,500 | — | ↗ |
| 2020-12-14 | Papkoff Jacqueline Sybil | Officer | S-Sale | D | Common Stock | 1,297 | 6.15 | 8.0K | 37,364 | — | ↗ |
| 2020-11-09 | Stamm Luisa M | Officer | S-Sale | D | Common Stock | 4,397 | 5.10 | 22.4K | 7,603 | — | ↗ |
| 2020-10-19 | Consylman Gina | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 15.55 | 311.0K | 20,000 | — | ↗ |
| 2020-08-07 | McHutchison John G | Director / Officer | S-Sale | D | Common Stock | 11,395 | 21.76 | 247.9K | 138,605 | — | ↗ |
| 2020-06-11 | RINGO WILLIAM R | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 20.47 | 204.7K | 10,000 | — | ↗ |
| 2020-06-11 | Mahony Susan | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 20.47 | 204.7K | 10,000 | — | ↗ |
| 2020-06-11 | LEWIS ALAN | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 20.47 | 204.7K | 10,000 | — | ↗ |
| 2020-06-11 | Kim Helen Susan | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 20.47 | 204.7K | 10,000 | — | ↗ |
| 2020-06-11 | HOLUBIAK MYRON Z | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 20.47 | 204.7K | 10,000 | — | ↗ |
| 2020-06-11 | DiMarchi Richard D | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 20.47 | 204.7K | 10,000 | — | ↗ |
| 2020-06-11 | ALTIG ANTHONY E | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 20.47 | 204.7K | 10,000 | — | ↗ |
| 2020-05-27 | Delaney William E IV | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 20.52 | 2.05M | 100,000 | — | ↗ |
| 2020-03-31 | Colonno Richard James | Officer | S-Sale | D | Common Stock | 7,812 | 15.04 | 117.5K | 137,009 | — | ↗ |
| 2020-03-30 | Papkoff Jacqueline Sybil | Officer | S-Sale | D | Common Stock | 1,254 | 14.22 | 17.8K | 38,661 | — | ↗ |
| 2020-03-27 | Russo Thomas Joseph | Officer | A-Award | A | Common Stock | 43,383 | 0.00 | — | 43,383 | — | ↗ |
| 2020-03-27 | Papkoff Jacqueline Sybil | Officer | A-Award | A | Common Stock | 17,000 | 0.00 | — | 39,915 | — | ↗ |
| 2020-03-27 | McHutchison John G | Director / Officer | A-Award | A | Common Stock | 50,000 | 0.00 | — | 150,000 | — | ↗ |
| 2020-03-27 | Colonno Richard James | Officer | A-Award | A | Common Stock | 17,000 | 0.00 | — | 144,821 | — | ↗ |
| 2020-03-26 | Okazaki Jason A | Officer | — | D | Common Stock | 0 | 0.00 | — | 2,500 | — | ↗ |
| 2020-02-28 | RINGO WILLIAM R | Director | G-Gift | D | Common Stock | 2,000 | 0.00 | — | 17,465 | — | ↗ |
| 2020-01-02 | Small Derek A | Director | A-Award | A | Common Stock | 125,000 | 0.00 | — | 828,791 | — | ↗ |
| 2019-12-13 | Papkoff Jacqueline Sybil | Officer | S-Sale | D | Common Stock | 1,460 | 21.00 | 30.7K | 22,915 | — | ↗ |
| 2019-12-12 | Colonno Richard James | Officer | M-Exempt | D | Stock Option (right to buy) | 33,061 | 7.03 | 232.4K | 166,939 | — | ↗ |
| 2019-11-06 | Stamm Luisa M | Officer | A-Award | A | Stock Option (right to buy) | 165,000 | 16.11 | 2.66M | 165,000 | — | ↗ |
| 2019-10-28 | Russo Thomas Joseph | Officer | A-Award | A | Stock Option (right to buy) | 185,000 | 15.69 | 2.90M | 185,000 | — | ↗ |
| 2019-10-01 | Samar Michael P. | Officer | A-Award | A | Common Stock | 2,500 | 0.00 | — | 20,327 | — | ↗ |
| 2019-10-01 | Papkoff Jacqueline Sybil | Officer | A-Award | A | Stock Options (right to buy) | 27,500 | 9.31 | 256.0K | 27,500 | — | ↗ |
| 2019-09-28 | McHutchison John G | Director / Officer | A-Award | A | Performance-based Restricted Stock Units | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2019-08-06 | McHutchison John G | Director / Officer | A-Award | A | Common Stock | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2019-05-17 | RINGO WILLIAM R | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 15.22 | 152.2K | 10,000 | — | ↗ |
| 2019-05-17 | Mahony Susan | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 15.22 | 152.2K | 10,000 | — | ↗ |
| 2019-05-17 | LEWIS ALAN | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 15.22 | 152.2K | 10,000 | — | ↗ |
| 2019-05-17 | Kim Helen Susan | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 15.22 | 152.2K | 10,000 | — | ↗ |
| 2019-05-17 | HOLUBIAK MYRON Z | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 15.22 | 152.2K | 10,000 | — | ↗ |
| 2019-05-17 | DiMarchi Richard D | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 15.22 | 152.2K | 10,000 | — | ↗ |
| 2019-05-17 | AUERBACH MARK | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 15.22 | 152.2K | 10,000 | — | ↗ |
| 2019-05-17 | ALTIG ANTHONY E | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 15.22 | 152.2K | 10,000 | — | ↗ |
| 2019-05-01 | Samar Michael P. | Officer | — | D | Stock Option (right to buy) | 17,000 | 24.19 | 411.2K | 0 | — | ↗ |
| 2019-03-29 | Small Derek A | Director / Officer | A-Award | A | Stock Option (right to buy) | 65,000 | 19.69 | 1.28M | 65,000 | — | ↗ |
| 2019-03-29 | Papkoff Jacqueline Sybil | Officer | A-Award | A | Stock Option (right to buy) | 27,500 | 19.69 | 541.5K | 27,500 | — | ↗ |
| 2019-03-29 | Lopatin Uri A | Officer | A-Award | A | Stock Option (right to buy) | 27,500 | 19.69 | 541.5K | 27,500 | — | ↗ |
| 2019-03-29 | Colonno Richard James | Officer | A-Award | A | Stock Option (right to buy) | 32,500 | 19.69 | 639.9K | 32,500 | — | ↗ |
| 2019-03-29 | COOPER GRAHAM K | Officer | A-Award | A | Stock Option (right to buy) | 35,000 | 19.69 | 689.2K | 35,000 | — | ↗ |
| 2018-12-12 | Papkoff Jacqueline Sybil | Officer | A-Award | A | Stock Option (right to buy) | 21,250 | 24.19 | 514.0K | 21,250 | — | ↗ |
| 2018-12-12 | Colonno Richard James | Officer | A-Award | A | Common Stock | 20,000 | 0.00 | — | 110,000 | — | ↗ |
| 2018-12-12 | COOPER GRAHAM K | Officer | A-Award | A | Common Stock | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2018-11-23 | Colonno Richard James | Officer | A-Award | A | Common Stock | 25,000 | 0.00 | — | 90,000 | — | ↗ |
| 2018-09-06 | Lopatin Uri A | Officer | S-Sale | D | Common Stock | 336 | 40.01 | 13.4K | 613,611 | — | ↗ |
| 2018-09-05 | Lopatin Uri A | Officer | S-Sale | D | Common Stock | 15,204 | 40.09 | 609.5K | 613,947 | — | ↗ |
| 2018-07-20 | Colonno Richard James | Officer | A-Award | A | Common Stock | 25,000 | 0.00 | — | 65,000 | — | ↗ |
| 2018-07-19 | Small Derek A | Director / Officer | P-Purchase | A | Common Stock | 1,200 | 41.77 | 50.1K | 669,291 | — | ↗ |
| 2018-07-02 | RINGO WILLIAM R | Director | M-Exempt | D | Stock Option (right to buy) | 1,000 | 7.20 | 7.2K | 49,000 | — | ↗ |
| 2018-06-01 | RINGO WILLIAM R | Director | M-Exempt | D | Stock Option (right to buy) | 1,000 | 7.20 | 7.2K | 50,000 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-166.0K
Shares Outstanding
15.89M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Jason A. Okazaki Chief Executive Officer and President | 647.5K | — | 661.7K | 573.6K | 585.0K | 15.2K | 2.48M | 49.75% | ↗ |
| 2 | 2025 | William E. Delaney IV, Ph.D. Chief Scientific Officer | 511.3K | — | 236.3K | 199.3K | 302.8K | 15.2K | 1.26M | 34.43% | ↗ |
| 3 | 2025 | Anuj Gaggar, M.D., Ph.D. | 502.9K | — | 236.3K | 189.1K | 303.0K | 14.8K | 1.25M | 34.14% | ↗ |
| 4 | 2024 | Jason A. Okazaki Chief Executive Officer and President | 626.3K | — | — | 637.7K | 488.6K | 14.6K | 1.77M | 36.09% | ↗ |
| 5 | 2024 | William E. Delaney IV, Ph.D. Chief Scientific Officer | 498.2K | — | — | 196.2K | 254.0K | 15.0K | 963.5K | 20.37% | ↗ |
| 6 | 2024 | Nicole S. White, Ph.D. Chief Manufacturing Officer | 424.0K | — | — | 171.7K | 217.5K | 14.3K | 827.5K | 20.75% | ↗ |
| 7 | 2023 | Jason A. Okazaki Chief Executive Officer and President | 600.0K | — | — | 306.1K | 453.6K | 14.0K | 1.37M | 22.28% | ↗ |
| 8 | 2023 | William E. Delaney IV, Ph.D. Chief Scientific Officer | 470.0K | — | — | 88.6K | 238.8K | 14.4K | 811.8K | 10.91% | ↗ |
| 9 | 2023 | Nicole S. White, Ph.D. Chief Manufacturing Officer | 400.0K | — | — | 88.6K | 203.2K | 13.7K | 705.5K | 12.55% | ↗ |
| 10 | 2023 | Nicole S. White, Ph.D. Chief Manufacturing Officer | 400.0K | — | — | 88.6K | 203.2K | 13.7K | 705.5K | 12.55% | ↗ |
| 11 | 2022 | Jason A. Okazaki Chief Operating Officer | 554.6K | — | 377.5K | 554.4K | 302.5K | 12.2K | 1.80M | 51.74% | ↗ |
| 12 | 2022 | Jason A. Okazaki Chief Executive Officer and President | 554.6K | — | 377.5K | 554.4K | 302.5K | 12.2K | 1.80M | 51.74% | ↗ |
| 13 | 2022 | John G. McHutchison, A.O., M.D. Chief Executive Officer and President | 844.6K | — | 338.4K | 564.1K | — | 12.2K | 1.76M | 51.30% | ↗ |
| 14 | 2022 | William E. Delaney IV, Ph.D. Chief Scientific Officer | 470.0K | — | 302.0K | 443.5K | 182.2K | 12.2K | 1.41M | 52.88% | ↗ |
| 15 | 2021 | John G. McHutchison, A.O., M.D. Chief Executive Officer and President | 841.5K | — | 419.5K | 979.3K | 614.5K | 11.6K | 2.87M | 48.80% | ↗ |
| 16 | 2021 | Jason A. Okazaki Chief Operating Officer | 532.5K | — | 184.5K | 252.4K | 297.8K | 11.6K | 1.28M | 34.16% | ↗ |
| 17 | 2021 | William E. Delaney IV, Ph.D. Chief Scientific Officer | 441.5K | — | 173.7K | 206.5K | 190.9K | 11.6K | 1.02M | 37.12% | ↗ |
| 18 | 2020 | Jason A. Okazaki Chief Operating Officer | 394.2K | 100.0K | 752.5K | 2.45M | 209.1K | — | 3.91M | 81.99% | ↗ |
| 19 | 2020 | Jason A. Okazaki Chief Operating Officer | 394.2K | 100.0K | 752.5K | 2.45M | 209.1K | — | 3.91M | 81.99% | ↗ |
| 20 | 2020 | John G. McHutchison, A.O., M.D. Chief Executive Officer and President | 817.5K | — | 722.5K | 1.03M | 615.0K | 11.4K | 3.19M | 54.80% | ↗ |
| 21 | 2020 | William E. Delaney IV, Ph.D. Chief Scientific Officer | 246.9K | 100.0K | 923.4K | 1.32M | 104.0K | — | 2.70M | 83.29% | ↗ |
| 22 | 2020 | William E. Delaney IV, Ph.D. Chief Scientific Officer | 246.9K | 100.0K | 923.4K | 1.32M | 104.0K | — | 2.70M | 83.29% | ↗ |
| 23 | 2020 | Thomas J. Russo, CFA Chief Financial Officer | 429.4K | — | 626.9K | — | 172.0K | 11.4K | 1.24M | 50.57% | ↗ |
| 24 | 2020 | Jacqueline S. Papkoff, Ph.D. Senior Vice President, Chief Scientific Officer, Microbiome | 417.5K | — | 245.7K | 319.3K | — | 11.4K | 993.8K | 56.84% | ↗ |
| 25 | 2019 | John G. McHutchison, A.O., M.D. Chief Executive Officer and President | 324.6K | 300.0K | 2.08M | 4.03M | 263.0K | 7.0K | 7.01M | 87.23% | ↗ |
| 26 | 2019 | John G. McHutchison, A.O., M.D. Chief Executive Officer and President | 324.6K | 300.0K | 2.08M | 4.03M | 263.0K | 7.0K | 7.01M | 87.23% | ↗ |
| 27 | 2019 | Derek A. Small Former Chief Executive Officer and President | 557.4K | — | 639.9K | 932.8K | 325.0K | 579.2K | 3.03M | 51.83% | ↗ |
| 28 | 2019 | Thomas J. Russo, CFA Chief Financial Officer | 77.4K | 100.0K | — | 1.92M | 32.0K | — | 2.13M | 90.18% | ↗ |
| 29 | 2019 | Thomas J. Russo, CFA Chief Financial Officer | 77.4K | 100.0K | — | 1.92M | 32.0K | — | 2.13M | 90.18% | ↗ |
| 30 | 2019 | Luisa M. Stamm, M.D., Ph.D. | 66.2K | 110.0K | 193.3K | 1.76M | — | 1.1K | 2.13M | 91.66% | ↗ |
| 31 | 2019 | Jacqueline S. Papkoff, Ph.D. Senior Vice President, Chief Scientific Officer, Microbiome | 395.0K | — | 270.7K | 536.5K | 172.0K | 12.7K | 1.39M | 58.20% | ↗ |
| 32 | 2018 | Graham Cooper Chief Financial Officer and Chief Operating Officer | 346.3K | — | 2.42M | 8.85M | 157.2K | 4.1K | 11.78M | 95.69% | ↗ |
| 33 | 2018 | David J. Barrett Former Chief Financial Officer and Chief Operating Officer | 179.2K | — | 4.32M | 26.9K | — | 801.1K | 5.32M | 81.59% | ↗ |
| 34 | 2018 | Derek A. Small Former Chief Executive Officer and President | 516.7K | — | 1.60M | 2.26M | 279.0K | 95.3K | 4.75M | 81.23% | ↗ |
| 35 | 2018 | Derek A. Small President and Chief Executive Officer | 516.7K | — | 1.60M | 2.26M | 279.0K | 95.3K | 4.75M | 81.23% | ↗ |
| 36 | 2018 | Jacqueline S. Papkoff, Ph.D. Senior Vice President, Chief Scientific Officer Microbiome | 270.0K | — | 257.0K | 3.87M | 104.9K | 10.2K | 4.51M | 91.46% | ↗ |
| 37 | 2018 | Jacqueline S. Papkoff, Ph.D. Senior Vice President, Chief Scientific Officer, Microbiome | 270.0K | — | 257.0K | — | 104.9K | 10.2K | 4.51M | 5.70% | ↗ |
| 38 | 2018 | Richard J. Colonno, Ph.D. Executive Vice President and Chief Scientific Officer of Virology Operations | 406.9K | — | 1.22M | 1.04M | 182.0K | 57.5K | 2.91M | 77.78% | ↗ |
| 39 | 2018 | Uri A. Lopatin, M.D. Chief Medical Officer | 386.3K | — | 368.6K | 521.1K | 146.4K | 75.9K | 1.50M | 59.34% | ↗ |
| 40 | 2017 | Richard J. Colonno, Ph.D. Chief Scientific Officer | 389.5K | — | 5.31M | 538.4K | 166.4K | — | 6.41M | 91.32% | ↗ |
| 41 | 2017 | Richard J. Colonno, Ph.D. Executive Vice President and Chief Scientific Officer of Virology Operations | 389.5K | — | 5.31M | 538.4K | 166.4K | — | 6.41M | 91.32% | ↗ |
| 42 | 2017 | Derek A. Small President and Chief Executive Officer | 470.8K | — | — | 717.9K | 250.0K | — | 1.44M | 49.90% | ↗ |
| 43 | 2017 | David J. Barrett Former Chief Financial Officer and Chief Operating Officer | 383.0K | — | — | 448.7K | 204.6K | 30.1K | 1.07M | 42.07% | ↗ |
| 44 | 2017 | David J. Barrett Chief Financial Officer and Chief Operating Officer | 413.2K | — | — | 448.7K | 204.6K | — | 1.07M | 42.07% | ↗ |
| 45 | 2017 | Uri A. Lopatin, M.D. Chief Medical Officer and Vice President of Research and Development | 375.4K | — | — | 224.3K | 128.7K | — | 728.4K | 30.80% | ↗ |
| 46 | 2017 | Uri A. Lopatin, M.D. Chief Medical Officer | 364.2K | — | — | 224.3K | 128.7K | 10.8K | 728.4K | 30.80% | ↗ |
| 47 | 2017 | Thomas E. Rollins Chief Development Officer | 368.8K | — | — | 179.5K | 103.8K | — | 652.0K | 27.53% | ↗ |
| 48 | 2016 | Richard J. Colonno, Ph.D. Executive Vice President and Chief Scientific Officer of Virology Operations | 377.3K | 75.0K | — | 1.06M | 125.0K | — | 1.63M | 64.65% | ↗ |
| 49 | 2016 | Richard J. Colonno, Ph.D. Chief Scientific Officer | 377.3K | 75.0K | — | 1.06M | 125.0K | — | 1.63M | 64.65% | ↗ |
| 50 | 2016 | Miguel S. Barbosa, Ph.D. Chief Scientific Officer of Microbiome Program and Head of Microbiome Program | 102.3K | — | — | 1.14M | 50.0K | — | 1.29M | 88.20% | ↗ |
| 51 | 2016 | Thomas E. Rollins Chief Development Officer | 351.9K | — | — | 613.0K | 92.0K | — | 1.06M | 58.00% | ↗ |
| 52 | 2016 | Derek A. Small President and Chief Executive Officer | 445.4K | — | — | — | 213.8K | — | 659.2K | 0.00% | ↗ |
| 53 | 2016 | David J. Barrett Former Chief Financial Officer and Chief Operating Officer | 471.0K | — | — | — | 177.3K | 30.1K | 578.4K | 0.00% | ↗ |
| 54 | 2016 | David J. Barrett Chief Financial Officer and Chief Operating Officer | 401.1K | — | — | — | 177.3K | — | 578.4K | 0.00% | ↗ |
| 55 | 2016 | Uri A. Lopatin, M.D. Chief Medical Officer and Vice President of Research and Development | 344.2K | — | — | — | 116.0K | — | 460.2K | 0.00% | ↗ |
| 56 | 2016 | Uri A. Lopatin, M.D. Chief Medical Officer | 344.2K | — | — | — | 116.0K | — | 460.2K | 0.00% | ↗ |
| 57 | 2015 | Derek A. Small President and Chief Executive Officer | 415.7K | — | — | — | 204.8K | — | 620.4K | 0.00% | ↗ |
| 58 | 2015 | Derek Small President and Chief Executive Officer | 411.3K | — | — | — | 204.8K | — | 616.0K | 0.00% | ↗ |
| 59 | 2015 | Russell H. Ellison, M.D. Former President and Chief Executive Officer | 59.4K | — | — | — | — | 516.9K | 576.3K | 0.00% | ↗ |
| 60 | 2015 | David J. Barrett Chief Financial Officer and Chief Operating Officer | 363.3K | — | — | — | 180.3K | — | 543.6K | 0.00% | ↗ |
| 61 | 2015 | Lee Arnold, M.D. Chief Scientific Officer | 315.0K | — | — | — | 85.1K | 82.0K | 482.0K | 0.00% | ↗ |
| 62 | 2015 | Uri A. Lopatin, M.D. Chief Medical Officer and Vice President of Research and Development | 319.0K | — | — | — | 95.7K | — | 414.7K | 0.00% | ↗ |
| 63 | 2014 | Russell H. Ellison, M.D. President and Chief Excecutive Officer | 465.0K | — | — | 4.69M | 142.5K | — | 5.30M | 88.54% | ↗ |
| 64 | 2014 | Russell H. Ellison, M.D. Former President and Chief Executive Officer | 465.0K | — | — | 4.69M | 142.5K | — | 5.30M | 88.54% | ↗ |
| 65 | 2014 | David J. Barrett Chief Financial Officer | 299.4K | — | — | 4.37M | 150.0K | — | 4.82M | 90.68% | ↗ |
| 66 | 2014 | David J. Barrett Chief Financial Officer and Chief Operating Officer | 299.4K | — | — | 4.37M | 150.0K | — | 4.82M | 90.68% | ↗ |
| 67 | 2014 | Uri Lopatin, M.D. Chief Medical Officer | 120.8K | 100.0K | — | 893.0K | 104.4K | — | 1.22M | 73.30% | ↗ |
| 68 | 2014 | Derek A. Small President and Chief Executive Officer | 160.4K | 150.0K | — | — | 116.7K | — | 427.1K | 0.00% | ↗ |
| 69 | 2014 | Derek Small President and Chief Executive Officer | 160.4K | 150.0K | — | — | 116.7K | — | 427.1K | 0.00% | ↗ |
| 70 | 2014 | Lee Arnold, M.D. Chief Scientific Officer | 144.4K | — | — | — | 51.2K | — | 195.6K | 0.00% | ↗ |
| 71 | 2013 | Russell H. Ellison, M.D. President and Chief Executive Officer | 375.0K | — | 147.5K | 322.7K | 18.8K | — | 541.3K | 86.88% | ↗ |
| 72 | 2013 | Russell H. Ellison, M.D. President and Chief Excecutive Officer | 375.0K | — | 147.5K | — | 18.8K | — | 541.3K | 27.25% | ↗ |
| 73 | 2013 | David J. Barrett Chief Financial Officer | 250.0K | — | 147.5K | — | 68.8K | — | 466.3K | 31.64% | ↗ |
| 74 | 2013 | Uri Lopatin, M.D. Chief Medical Officer | — | — | — | — | — | — | — | — | ↗ |
| 75 | 2013 | Lee Arnold, M.D. Chief Scientific Officer | — | — | — | — | — | — | — | — | ↗ |
| 76 | 2013 | Derek Small President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 77 | 2012 | Russell H. Ellison, M.D. President and Chief Executive Officer | 375.0K | 75.0K | — | — | 175.8K | — | 948.5K | 0.00% | ↗ |
| 78 | 2012 | Russell H. Ellison, M.D. President and Chief Executive Officer | 375.0K | 75.0K | — | 322.7K | 175.8K | — | 948.5K | 34.03% | ↗ |
| 79 | 2012 | David J. Barrett Chief Financial Officer | 250.0K | — | — | — | 67.5K | — | 532.7K | 0.00% | ↗ |
| 80 | 2012 | David J. Barrett Chief Financial Officer | 250.0K | — | — | 215.2K | 67.5K | — | 532.7K | 40.39% | ↗ |
| 81 | 2012 | Thomas Rowland Chief Business Officer | 187.5K | — | — | 161.4K | — | — | 348.9K | 46.25% | ↗ |
| 82 | 2011 | Thomas Rowland Chief Business Officer | 83.3K | — | — | 1.28M | 15.0K | 16.7K | 1.40M | 91.71% | ↗ |
| 83 | 2011 | Thomas Rowland Chief Business Office | 83.3K | — | — | 1.28M | 15.0K | 16.7K | 1.40M | 91.71% | ↗ |
| 84 | 2011 | Russell H. Ellison, M.D. President and Chief Executive Officer | 375.0K | 325.0K | — | — | 183.8K | — | 883.8K | 0.00% | ↗ |
| 85 | 2011 | David J. Barrett Chief Financial Officer | 250.0K | 250.0K | — | — | 60.0K | — | 560.0K | 0.00% | ↗ |
| 86 | 2010 | Russell H. Ellison, M.D. President and Chief Executive Officer | — | — | — | — | — | 210.0K | 3.00M | 0.00% | ↗ |
| 87 | 2010 | Russell H. Ellison, M.D. President and CEO | — | — | — | 2.79M | — | 210.0K | 3.00M | 92.99% | ↗ |
| 88 | 2010 | David J. Barrett Chief Financial Officer | — | — | — | 1.49M | — | 105.0K | 1.59M | 93.40% | ↗ |
| 89 | 2010 | David J. Barrett Chief Financial Officer | — | — | — | — | — | 105.0K | 1.59M | 0.00% | ↗ |
| 90 | 2010 | Thomas Rowland Chief Business Office | — | — | — | 168.7K | — | — | 168.7K | 100.00% | ↗ |
| 91 | 2010 | Thomas Rowland Chief Business Officer | — | — | — | — | — | — | 168.7K | 0.00% | ↗ |
| 92 | 2009 | Thomas Rowland Chief Business Office | 50.0K | — | — | — | — | 62.5K | 112.5K | 0.00% | ↗ |
| 93 | 2009 | Russell H. Ellison, M.D. President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 94 | 2009 | Russell H. Ellison, M.D. President and CEO | — | — | — | — | — | — | — | — | ↗ |
| 95 | 2009 | David J. Barrett Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 96 | 2009 | David J. Barrett Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jason A. Okazaki | Chief Executive Officer, President & Director | 1M | male |
| William E. Delaney | Chief Scientific Officer | 829.4K | — |
| Anuj Gaggar | Chief Medical Officer | 820.7K | — |
| Nicole S. White | Chief Manufacturing Officer | 655.8K | — |
| Thomas E. Rollins | Executive Officer | 472.6K | male |
| Katie Kitrinos | Senior Vice President of Preclinical Research & Development | — | female |
| Jeanette Bjorkquist | Principal Financial Officer, Executive Director of Accounting & Treasury | — | female |
| Jennifer A. Troia MHROD SHRM-SCP SPHR | Chief Human Resources Officer | — | female |
| Amy Figueroa | Investor Relations Consultant | — | — |
| Shannon Ryan | Senior Vice President of Investor Relations, Corporate Affairs & Alliance Management | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ASMB
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
